- JSP coordinators told to work for victory of TDP-JSP alliance
- Need to increase agri export stressed
- Gold rate in Vijayawada today slashes, check the rates on 5 March, 2024
- Gold rates in Hyderabad slashes today, check the rates on 05 March, 2024
- Gold rates in Delhi today slashes, check the rates on 05 March, 2024
- TDP-Jana Sena to hold BC Jayaho today, to announce BC declaration
- Hyderabad: Man murders wife over suspected affair
- GHMC receives 187 ‘Prajavani’ applications
- VJIM’s Milan-24 festival concludes
- AAP plans to contest in 7 Lok Sabha, 50 Assembly seats
Covaxin shows 78% efficacy in phase 3 trials
The Drugs Controller General of India's Subject Expert Committee (SEC) has approved Bharat Biotech' phase 3 trial efficacy data after questions were raised over the delay in announcing results
Hyderabad: The Drugs Controller General of India's Subject Expert Committee (SEC) has approved Bharat Biotech' phase 3 trial efficacy data after questions were raised over the delay in announcing results.
According to the data submitted, Covaxin has shown the efficacy of 77.8 per cent from the trial conducted on 25,800 subjects. The vaccine had earlier received emergency approval from the DCGI and is one of the three vaccines approved for the mass use in India.
The Hyderabad-based biotechnology company had earlier submitted phase-III clinical trial data of its Covid-19 vaccine Covaxin to the drug regulator.
Trial data of phase 3 is crucial as it will provide details of the efficacy of the vaccine, which was developed in association with the Indian Council of Medical Research (ICMR).
The phase 3 trial data is also required for getting emergency use listing (EUL) from the World Health Organisation (WHO). The WHO has accepted Bharat Biotech's Expression of Interest (EoI) for EUL for Covaxin and scheduled a pre-submission meeting on Wednesday.
The complete results of Covaxin's phase 3 trial data will be made public during July. In March, the vaccine maker had said Covaxin demonstrated 81 per cent interim efficacy in preventing Covid-19 in those without prior infection after the second dose.
In January, DCGI had granted permission for emergency use of Covaxin based on its phase-I and phase 3 clinical trial data.